Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGF βi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
Conditions: Anatomic Stage IV Breast Cancer AJCC v8; HER2-Negative Breast Carcinoma Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Drug: Gemcitabine; Procedure: Magnetic Resonance Imaging; Biological: Naxitamab; Biological: Universal Donor Expanded TGF-beta-imprinted NK Cells Sponsor: Margaret Gatti-Mays Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 7, 2023 Category: Research Source Type: clinical trials
Phase IB Followed by Phase II Study of Trastuzumab Combined With Autologous T Cells Expressing an Antibody-dependent Cell Cytotoxicity Receptor (ADCC-R) and an Erythropoietin Receptor (Epo-R) in HER2+ Advanced Breast Cancer and Other Solid Tumors
Conditions: HER2+ Advanced Breast Cancer; Other Solid Tumors Interventions: Drug: ADCC-R-Epo-R T-cells + Trastuzumab; Drug: Erythropoietin beta; Drug: Fludarabine and Cyclophosphosphamide Sponsor: National University Hospital, Singapore Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 7, 2023 Category: Research Source Type: clinical trials
Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGF βi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
Conditions: Anatomic Stage IV Breast Cancer AJCC v8; HER2-Negative Breast Carcinoma Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Drug: Gemcitabine; Procedure: Magnetic Resonance Imaging; Biological: Naxitamab; Biological: Universal Donor Expanded TGF-beta-imprinted NK Cells Sponsor: Margaret Gatti-Mays Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 7, 2023 Category: Research Source Type: clinical trials
Phase IB Followed by Phase II Study of Trastuzumab Combined With Autologous T Cells Expressing an Antibody-dependent Cell Cytotoxicity Receptor (ADCC-R) and an Erythropoietin Receptor (Epo-R) in HER2+ Advanced Breast Cancer and Other Solid Tumors
Conditions: HER2+ Advanced Breast Cancer; Other Solid Tumors Interventions: Drug: ADCC-R-Epo-R T-cells + Trastuzumab; Drug: Erythropoietin beta; Drug: Fludarabine and Cyclophosphosphamide Sponsor: National University Hospital, Singapore Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 7, 2023 Category: Research Source Type: clinical trials
Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGF βi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
Conditions: Anatomic Stage IV Breast Cancer AJCC v8; HER2-Negative Breast Carcinoma Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Drug: Gemcitabine; Procedure: Magnetic Resonance Imaging; Biological: Naxitamab; Biological: Universal Donor Expanded TGF-beta-imprinted NK Cells Sponsor: Margaret Gatti-Mays Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 7, 2023 Category: Research Source Type: clinical trials
Phase IB Followed by Phase II Study of Trastuzumab Combined With Autologous T Cells Expressing an Antibody-dependent Cell Cytotoxicity Receptor (ADCC-R) and an Erythropoietin Receptor (Epo-R) in HER2+ Advanced Breast Cancer and Other Solid Tumors
Conditions: HER2+ Advanced Breast Cancer; Other Solid Tumors Interventions: Drug: ADCC-R-Epo-R T-cells + Trastuzumab; Drug: Erythropoietin beta; Drug: Fludarabine and Cyclophosphosphamide Sponsor: National University Hospital, Singapore Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 7, 2023 Category: Research Source Type: clinical trials
Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGF βi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
Conditions: Anatomic Stage IV Breast Cancer AJCC v8; HER2-Negative Breast Carcinoma Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Drug: Gemcitabine; Procedure: Magnetic Resonance Imaging; Biological: Naxitamab; Biological: Universal Donor Expanded TGF-beta-imprinted NK Cells Sponsor: Margaret Gatti-Mays Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 7, 2023 Category: Research Source Type: clinical trials
Phase IB Followed by Phase II Study of Trastuzumab Combined With Autologous T Cells Expressing an Antibody-dependent Cell Cytotoxicity Receptor (ADCC-R) and an Erythropoietin Receptor (Epo-R) in HER2+ Advanced Breast Cancer and Other Solid Tumors
Conditions: HER2+ Advanced Breast Cancer; Other Solid Tumors Interventions: Drug: ADCC-R-Epo-R T-cells + Trastuzumab; Drug: Erythropoietin beta; Drug: Fludarabine and Cyclophosphosphamide Sponsor: National University Hospital, Singapore Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 7, 2023 Category: Research Source Type: clinical trials
Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGF βi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
Conditions: Anatomic Stage IV Breast Cancer AJCC v8; HER2-Negative Breast Carcinoma Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Drug: Gemcitabine; Procedure: Magnetic Resonance Imaging; Biological: Naxitamab; Biological: Universal Donor Expanded TGF-beta-imprinted NK Cells Sponsor: Margaret Gatti-Mays Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 7, 2023 Category: Research Source Type: clinical trials
